Seroatlas · Human Serome Atlas

MAP2K2

Dual specificity mitogen-activated protein kinase kinase 2

Also known as: MEK2, MP2K2_HUMAN, PRKMK2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P36507
Gene
MAP2K2
Ensembl
ENSG00000126934
Chromosome
19
Canonical length
400 aa
Protein class
Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, RAS pathway related proteins
Subcellular location
Cytosol,Mid piece,Principal piece,End piece

OverviewNCBI Gene

The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

400 residues, UniProt reviewed canonical sequence.

>P36507|MAP2K2
     1  MLARRKPVLP ALTINPTIAE GPSPTSEGAS EANLVDLQKK LEELELDEQQ KKRLEAFLTQ
    61  KAKVGELKDD DFERISELGA GNGGVVTKVQ HRPSGLIMAR KLIHLEIKPA IRNQIIRELQ
   121  VLHECNSPYI VGFYGAFYSD GEISICMEHM DGGSLDQVLK EAKRIPEEIL GKVSIAVLRG
   181  LAYLREKHQI MHRDVKPSNI LVNSRGEIKL CDFGVSGQLI DSMANSFVGT RSYMAPERLQ
   241  GTHYSVQSDI WSMGLSLVEL AVGRYPIPPP DAKELEAIFG RPVVDGEEGE PHSISPRPRP
   301  PGRPVSGHGM DSRPAMAIFE LLDYIVNEPP PKLPNGVFTP DFQEFVNKCL IKNPAERADL
   361  KMLTNHTFIK RSEVEEVDFA GWLCKTLRLN QPGTPTRTAV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MAP2K2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.32
Highest tissue expression
263 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 263 nTPM
  • choroid plexus: 149 nTPM
  • tongue: 122 nTPM
  • heart muscle: 121 nTPM
  • duodenum: 116 nTPM
  • cerebral cortex: 115 nTPM

Single-cell type

  • late spermatids: 1,280 nCPM
  • esophageal apical cells: 392 nCPM
  • erythrocyte progenitors: 319 nCPM
  • early spermatids: 291 nCPM
  • colonocytes: 271 nCPM
  • enterocytes: 161 nCPM

Immune cell

  • eosinophil: 38 nTPM
  • basophil: 20 nTPM
  • NK-cell: 16 nTPM
  • naive B-cell: 14 nTPM
  • gdT-cell: 14 nTPM
  • memory CD8 T-cell: 13 nTPM

Brain region

  • pons: 108 nTPM
  • midbrain: 104 nTPM
  • cerebellum: 100 nTPM
  • thalamus: 99 nTPM
  • choroid plexus: 95 nTPM
  • cerebral cortex: 94 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MAP2K2.

Disease | AllUniProt

Conditions MAP2K2 is implicated in, by any mechanism.

Disease | GeneticClinVar

22 pathogenic / likely-pathogenic of 1,025 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.33
gnomAD pLI
0.97
gnomAD missense Z
1.87
DepMap mean gene effect
-0.12
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MAP2K2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MAP2K2 as an antibody target. Whether an autoantibody or antibody against MAP2K2 could matter depends on whether native MAP2K2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MAP2K2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MAP2K2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/MAP2K2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...